Signal inhibitory receptor on leukocytes-1 recognizes bacterial and endogenous amphipathic α-helical peptides

Matevž Rumpret1,2 | Helen J. von Richthofen1,2 | Maarten van der Linden1 | Geertje H. A. Westerlaken1,2 | Cami Talavera Ormeño2,3 | Jos A. G. van Strijp4 | Meytal Landau5 | Huib Ovaa2,3† | Nina M. van Sorge4 | Linde Meyaar1,2

1Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands 
2Oncode Institute, Utrecht, The Netherlands
3Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands
4Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
5Department of Biology, Technion Israel Institute of Technology, Haifa, Israel

Correspondence
Linde Meyaar, Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Lundlaan 6, 3584 EA Utrecht, The Netherlands.
Email: l.meyaard@umcutrecht.nl

Present address
Nina M. van Sorge, Department of Medical Microbiology and Infection Prevention, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Location Amsterdam Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Funding information
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO), Grant/Award Number: 91815608

Abstract
Signal inhibitory receptor on leukocytes-1 (SIRL-1) is a negative regulator of myeloid cell function and dampens antimicrobial responses. We here show that different species of the genus *Staphylococcus* secrete SIRL-1-engaging factors. By screening a library of single-gene transposon mutants in *Staphylococcus aureus*, we identified these factors as phenol-soluble modulins (PSMs). PSMs are amphipathic α-helical peptides involved in multiple aspects of staphylococcal virulence and physiology. They are cytotoxic and activate the chemotactic formyl peptide receptor 2 (FPR2) on immune cells. Human cathelicidin LL-37 is also an amphipathic α-helical peptide with antimicrobial and chemotactic activities, structurally and functionally similar to α-type PSMs. We demonstrate that α-type PSMs from multiple staphylococcal species as well as human cathelicidin LL-37 activate SIRL-1, suggesting that SIRL-1 recognizes α-helical peptides with an amphipathic arrangement of hydrophobicity, although we were not able to show direct binding to SIRL-1. Upon rational peptide design, we identified artificial peptides in which the capacity to ligate SIRL-1 is segregated from cytotoxic and FPR2-activating properties, allowing specific engagement of SIRL-1. In conclusion, we propose staphylococcal PSMs and human LL-37 as a potential new class of natural ligands for SIRL-1.

KEYWORDS
cathelicidin LL-37, phenol-soluble modulin, SIRL-1, *Staphylococcus*

Abbreviations: DAMP, damage-associated molecular pattern; FPR2, formyl peptide receptor 2; LAIR-1, leukocyte-associated immunoglobulin-like receptor 1; LDH, lactate dehydrogenase; NFAT, nuclear factor of activated T cells; NTML, Nebraska transposon mutant library; PAMP, pathogen-associated molecular pattern; PMA, phorbol 12-myristate 13-acetate; PRR, pattern recognition receptor; PSM, phenol-soluble modulin; QS, quorum sensing; SIRL-1, signal inhibitory receptor on leukocytes-1.

†Deceased.
1 | INTRODUCTION

Our defense system typically recognizes microbes through pattern recognition receptors (PRRs), which interact with pathogen-associated molecular patterns (PAMPs).1 Besides extrinsic stimuli such as bacteria, endogenous damage- or danger-associated molecular patterns (DAMPs) such as defensins, heat shock proteins, cathelicidin LL-37, and some S100 proteins also interact with PRRs and initiate or potentiate immune responses.5,3 Nevertheless, excessive triggering of PRRs and other activating immune receptors can lead to immune system overactivation, induce immunopathology, and cause tissue damage. To prevent disproportionate activation, inhibitory immune receptors control the activation of immune cells. They dampen and provide context to activation signals that immune cells receive when encountering a microbial or endogenous trigger and raise the activation threshold.4

Signal inhibitory receptor on leukocytes-1 (SIRL-1) is an inhibitory immune receptor expressed on granulocytes and monocytes in the blood5 and monocytes in the lung.6 A genetic polymorphism regulating SIRL-1 expression levels on monocytes is associated with the inflammatory skin disease atopic dermatitis.7 Upon SIRL-1 engagement, two immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic domain become phosphorylated and recruit Src homology 2 domain-containing tyrosine phosphatases 1 and 2 to relay inhibitory signals.8 Neutrophils possess potent mechanisms for microbe recognition and clearance and are critical immune cells in the defense against bacteria. We have shown that SIRL-1 engagement on neutrophils dampens reactive oxygen species production and neutrophil extracellular trap formation.8-10 Recently, we have revealed that SIRL-1 is engaged by the endogenous S100 protein family of DAMPs.11 We have also demonstrated that SIRL-1 is downregulated on in vitro-activated neutrophils9 and neutrophils present at the site of infection.12 Therefore, we have proposed that SIRL-1 acts as a disinhibition receptor: once the threshold for activation provided by SIRL-1 is passed, SIRL-1 down-regulation allows for the rapid deployment of neutrophil effector mechanisms.4

The human skin is covered with a variety of microbes that provide benefit to the host.13 However, potentially pathogenic microbes are also commonly present among healthy microbiota communities and can, depending on the location or context in which they appear, cause infections.14 To prevent infections, a robust first line of microbe-controlling mechanisms, such as the skin’s acidity, low moisture content, and the production of antimicrobial peptides such as β-defensins, dermcidin, some S100 proteins, and cathelicidin LL-37, is established in the skin.15-18 The skin-residing Gram-positive bacteria of the genus Staphylococcus are particularly well adapted to life under such conditions.15,16 Staphylococcus comprises bacterial species with vastly different pathogenic potential. The well-characterized Staphylococcus aureus can exhibit a commensal-like lifestyle, and commonly colonizes the human nares and skin.20,21 It is often present on the skin of patients with atopic dermatitis.22 S. aureus is also a well-known pathogen,20 causing skin and soft tissue infections and even invasive systemic infections.23,24 Staphylococcus epidermidis fulfills a similar dual role in its interaction with the host. It is the most common colonizer of human skin, but can also cause disease, although generally in a hospital setting and not in healthy individuals.25-27 Many well-characterized virulence factors that increase staphylococcal pathogenicity and promote survival when encountering the host’s defense mechanisms have been described, predominantly in S. aureus.28-31 In contrast, features or molecules that promote staphylococcal commensalism are less well understood. Similarly, host factors contributing to the maintenance of tolerance to microbes are mainly unknown. Multiple inhibitory immune receptors interact with microbes.32 Here, we investigated the SIRL-1 engagement by Staphylococcus and identified a new group of staphyloccocal and endogenous ligands for SIRL-1.

2 | MATERIALS AND METHODS

2.1 | Bacterial strains and plasmids

Bacterial strains and plasmids used are described in Tables 1 and 2, respectively. All strains were grown overnight in tryptic soy broth (T8907, Sigma–Aldrich, St. Louis, Missouri, USA) at 37°C with agitation. Plasmid-harboring strains were grown in tryptic soy broth supplemented with 25 µg/ml tetracycline (T7660, Sigma–Aldrich, St. Louis, Missouri, USA) overnight at 37°C with agitation. The next day, bacterial cultures were centrifuged for 3 min at 2700 g, and the supernatant was filtered through a 0.2 µm filter. Strains of the Nebraska transposon mutant library (NTML) screening array were grown in 900 µl tryptic soy broth supplemented with 5 µg/ml erythromycin (E5389, Sigma–Aldrich, St. Louis, Missouri, USA) in deep 96-well plates overnight at 37°C without agitation. The next day, bacterial cultures were centrifuged for 3 min at 2700 g, and the supernatant was collected without filtration.

2.2 | Peptide design and analysis

We designed twenty-eight 18 AA residue long peptides comprising only amino acids with the highest α-helical
propensities: lysine as a positively charged, glutamic acid as a negatively charged, glutamine as a polar uncharged, and leucine as a hydrophobic amino acid. Sequence alignment was performed with Clustal Omega, secondary structure prediction was performed with Jpred4, and screening of peptides for specific α-helical properties was performed with HeliQuest. The 28 designed peptides are shown in Table 3.

### 2.3 Peptide synthesis

*S. aureus* PSMz3, N′-formyl-PSMz3, C′-N′ reversed sequence PSMz3, all-D-PSMz3, N′-formyl-δ-toxin, and N′-formyl-PSMβ1 were custom synthesized by GenScript (Piscataway, New Jersey, USA) at 95% purity. Human cathelicidin LL-37 was custom synthesized by GenScript (Piscataway, New Jersey, USA) at 95% purity or purchased from AnaSpec (AS-61302).

### 2.4 Antibody generation

Mouse anti-human-SIRL-1 antibody clone 3D3 was generated as described previously. BALB/c mice were subcutaneously injected with 50 µg SIRL-1 ectodomain (in-house production, as described in Ref. [5]), and injections were repeated 2 and 3 weeks after the first injection. Mice were sacrificed 3 days after the final injection, and we fused splenic PBMCs with SP2/0 cells using standard hybridoma technology. We screened the resulting hybridoma clones for specific binding to SIRL-1-transfected RBL-2H3 cells. We obtained monoclonal hybridoma cells by performing limiting dilution, screened them again for SIRL-1 binding, and selected clone 3D3 as a prominent SIRL-1 binder. We purified the mAb clone 3D3 from the monoclonal hybridoma cell supernatant using a HiTrap Protein G HP column (17-0405-01, GE Life sciences, Fairfield, Connecticut, USA).

### TABLE 1 Bacterial strains used in this study

| Bacterial strains | Source |
|-------------------|--------|
| S. aureus LAC wt  | [33]   |
| S. aureus LAC Δagr| [33]   |
| S. aureus LAC ΔPSM| [34]   |
| S. aureus LAC ΔPSMα1-4 | [33] |
| S. aureus LAC ΔPSMβ1-2 | [33] |
| S. aureus LAC Δhld| [33]   |
| S. aureus MW2 wt  | [33]   |
| S. aureus MW2 Δagr| [33]   |
| S. aureus MW2 ΔPSM| [35]   |
| S. aureus MW2 ΔPSMα1-4 | [33] |
| S. aureus MW2 ΔPSMβ1-2 | [33] |
| S. aureus MW2 Δhld| [33]   |
| S. epidermidis ATCC 49134 | Own |
| S. capitis ATCC 35661 | Own |
| S. carnosus TM-300 | Own |
| S. haemolyticus KV-116 | Own |
| S. hominis KV-111 | Own |
| S. warneri KV-112 | Own |
| S. saprophyticus ATCC 35552 | Own |
| S. lugdunensis M23590, HM-141a | NIAID, NIH |
| S. caprae C87, HM-246b | NIAID, NIH |
| Nebraska transposon mutant library (NTML), NR-48501

| Provided by BEI Resources, NIAID, NIH, as part of the Human Microbiome Project. |
| Provided by NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH, as part of the Human Microbiome Project. |
| Provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) for distribution by BEI Resources, NIAID, NIH. |

### TABLE 2 Plasmids used in this study

| Plasmids | Description | Source |
|----------|-------------|--------|
| pTXΔ16   | Tetracycline (Tet) resistance, control plasmid | [33]   |
| pTXΔ16–PSMα | Tet resistance, psmα1-4 genes constitutively expressed through xylose promoter | [33]   |
| pTXΔ16–PSMβ | Tet resistance, psmβ1-2 genes constitutively expressed through xylose promoter | [36]   |
| pTXΔ16–hld | Tet resistance, hld gene constitutively expressed through xylose promoter | [37]   |
2.5 | 2B4 NFAT–GFP reporter cell assay

The 2B4 cell line is a T-cell hybridoma cell line. In the 2B4 NFAT–GFP reporter cell lines, extracellular domains of human leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) and SIRL-1 are fused to the transmembrane and intracellular domains of human CD3ζ. Ligation of either the cells’ endogenous CD3ζ or a hLAIR-1-CD3ζ or hSIRL-1-CD3ζ chimera by an antibody or a ligand results in nuclear factor of activated T-cells (NFAT) promoter-driven GFP expression. Reporter cells were maintained in RPMI 1640 (52400-041, Life Technologies, Carlsbad, California, USA) supplemented with 10% heat-inactivated fetal bovine serum (Biowest, Nuaillé, France) and 50 U/ml penicillin–streptomycin (11528876, Life Technologies, Carlsbad, California, USA) (referred to as culture medium thereafter). The NFAT–GFP reporter cell assay was performed with wt–CD3ζ, hSIRL-1-CD3ζ, or hLAIR-1-CD3ζ NFAT–GFP reporter cells. Nunc MaxiSorp (442404, ThermoFisher Scientific, Waltham, Massachusetts, USA) (Figures 1-4, 5A,B) or Greiner Bio-One (655101, Kremsmünster, Austria) (Figure 5C) 96-well flat-bottom plates were coated overnight with PBS, and 0.5 × 10⁴ reporter cells in 200 µl culture medium were seeded to each well. Plates were incubated overnight in a cell culture incubator at 37°C and 5% CO₂. Where indicated, reporter cells were pre-incubated with mouse-anti-SIRL-1 clones 1A5 or 3D3 or mouse-anti-LAIR-1 clone 8A8 for 30 min before seeding to the plate without washing. For the anti-CD3 mAb control in reporter assays with pre-incubation with antibodies, 1 µg/ml anti-mouse-CD3 was coated to the plate. The next day, GFP expression was measured by flow cytometry (LSR Fortessa; BD Bioscience, Franklin Lakes, New Jersey, USA) and analyzed with FlowJo software (version 10.0.7r2).

2.6 | 2B4 NFAT translocation assay

hSIRL-1-CD3ζ reporter cells were stimulated for 30 min on 96-well MaxiSorp flat-bottom plates coated overnight at 4°C with PSMα3, LL-37, or the same control antibodies as were used in the 2B4 NFAT–GFP reporter assay. In addition, cells were stimulated with 50 ng/ml phorbol 12-myristate 13-acetate (PMA; P8139, Sigma–Aldrich, St. Louis, Missouri, USA) and 3.75 µM ionomycin (I0634, Sigma–Aldrich, St. Louis, Missouri, USA). After 30 min, cells were fixed by a 15-minute incubation in 3.7% paraformaldehyde (F8773, Sigma–Aldrich, St. Louis, Missouri, USA). Cells were then washed three times with PBS, and 0.5 × 10⁴ reporter cells in 200 µl culture medium were seeded to each well. Plates were incubated overnight in a cell culture incubator at 37°C and 5% CO₂. Where indicated, reporter cells were pre-incubated with mouse-anti-SIRL-1 clones 1A5 or 3D3 or mouse-anti-LAIR-1 clone 8A8 for 30 min before seeding to the plate without washing. For the anti-CD3 mAb control in reporter assays with pre-incubation with antibodies, 1 µg/ml anti-mouse-CD3 was coated to the plate. The next day, GFP expression was measured by flow cytometry (LSR Fortessa; BD Bioscience, Franklin Lakes, New Jersey, USA) and analyzed with FlowJo software (version 10.0.7r2).

### Table 3 Sequences of the 28 designed peptides

| No. peptide | Sequence | No. peptide | Sequence |
|-------------|----------|-------------|----------|
| 1           | LQLLQQQLQLQQLQQLQQLQ | 15         | LQLLQQQLQLQQLQQLQQLQ |
| 2           | LQLLQQQLQLQQLQQLQQLQ | 16         | LQLLQQQLQLQQLQQLQQLQ |
| 3           | LQLLQQQLQLQQLQQLQQLQ | 17         | LQLLQQQLQLQQLQQLQQLQ |
| 4           | LQLLQQQLQLQQLQQLQQLQ | 18         | LQLLQQQLQLQQLQQLQQLQ |
| 5           | LQLLQQQLQLQQLQQLQQLQ | 19         | LQLLQQQLQLQQLQQLQQLQ |
| 6           | LQLLQQQLQLQQLQQLQQLQ | 20         | LQLLQQQLQLQQLQQLQQLQ |
| 7           | LQLLQQQLQLQQLQQLQQLQ | 21         | LQLLQQQLQLQQLQQLQQLQ |
| 8           | LQLLQQQLQLQQLQQLQQLQ | 22         | LQLLQQQLQLQQLQQLQQLQ |
| 9           | LQLLQQQLQLQQLQQLQQLQ | 23         | LQLLQQQLQLQQLQQLQQLQ |
| 10          | LQLLQQQLQLQQLQQLQQLQ | 24         | LQLLQQQLQLQQLQQLQQLQ |
| 11          | LQLLQQQLQLQQLQQLQQLQ | 25         | LQLLQQQLQLQQLQQLQQLQ |
| 12          | LQLLQQQLQLQQLQQLQQLQ | 26         | LQLLQQQLQLQQLQQLQQLQ |
| 13          | LQLLQQQLQLQQLQQLQQLQ | 27         | LQLLQQQLQLQQLQQLQQLQ |
| 14          | LQLLQQQLQLQQLQQLQQLQ | 28         | LQLLQQQLQLQQLQQLQQLQ |
PBS with 1% BSA and 0.1% Triton X-100 (X100, Sigma–Aldrich, St. Louis, Missouri, USA). After three washes with PBS with 1% BSA, NFAT translocation was measured by imaging flow cytometry (Imagestream; Amnis, Austin, Texas, USA). Data were analyzed using the IDEAS software (Amnis, Austin, Texas, USA). Nuclear translocation of NFAT was assessed by analyzing the overlay between the nuclear signal (DRAQ5) and NFAT (Alexa Fluor488). We reported the percentage of the cells with a DRAQ5–Alexa Fluor488 similarity score above 2.5 (as assessed by the Similarity Feature in IDEAS software) as the percentage of cells with nuclear NFAT.

2.7 Lactate dehydrogenase (LDH) release cytotoxicity assay

LDH release cytotoxicity assay was performed using the Pierce LDH Cytotoxicity Assay Kit (88953, ThermoFisher Scientific, Waltham, Massachusetts, USA). hSIRL-1-CD3ζ GFP reporter cells were routinely cultured as described above. For the LDH assay, cells were transferred to RPMI 1640 without phenol red (11835063, ThermoFisher Scientific, Waltham, Massachusetts, USA) supplemented with 5% heat-inactivated fetal bovine serum and seeded to a flat-bottom 96-well plate at 20 000 cells per well in 100 µl medium. Cells were incubated overnight in a cell culture incubator at 37°C and 5% CO2. The next day, 10 µl of peptides dissolved in water was added to the cells to a final concentration of 10 µM. Water and manufacturer-provided lysis buffer were used as controls. Cells were incubated in a cell culture incubator at 37°C and 5% CO2 for 45 min. After incubation, supernatants were collected, and the detection of LDH was performed following the manufacturer’s instructions. Absorbance at 490 and 680 nm was measured. The 680 nm absorbance values were subtracted from the 490 nm absorbance values. Values were normalized to

**FIGURE 1** Supernatants of different staphylococcal species activate SIRL-1. Wild-type, hLAIR-1-CD3ζ, or hSIRL-1-CD3ζ-expressing NFAT–GFP reporter cells were stimulated overnight with plate-coated control antibodies, collagen, tryptic soy broth, or supernatants of overnight cultures of different *Staphylococcus* sp. grown in tryptic soy broth. GFP expression upon overnight stimulation was measured by flow cytometry. (A) The percentage of GFP-positive reporter cells in response to stimulation with plate-coated PBS (negative control), anti-mouse CD3, anti-LAIR-1, and anti-SIRL-1-specific antibodies, the LAIR-1 ligand collagen (positive controls), and overnight culture supernatants of the *Staphylococcus aureus* strains LAC and MW2 and tryptic soy broth as control. (B) Representative dot plots showing the percentage of GFP-positive reporter cells after stimulation with *S. aureus* strains LAC and MW2, with tryptic soy broth as control. (C) The percentage of GFP-positive reporter cells in response to stimulation with plate-coated supernatants of nine other staphylococcal species. Mean and SD of three independent experiments are displayed. Student’s *t*-test with the Holm–Šidák multiple-comparison correction. Significance is indicated for the comparison of hLAIR-1-CD3ζ to hSIRL-1-CD3ζ. *p < .05; **p < .01; ***p < .001; ns = not significant.
water-treated cells as 0% cytotoxicity and lysis-buffer-treated cells as 100% cytotoxicity. The experiment was performed in duplicates.

2.8 Formyl peptide receptor 2 (FPR2)-mediated Ca\(^{2+}\) mobilization assay

HL-60 FPR2 cells\(^{52}\) were routinely cultured in culture medium (described above). Prior to the assay, cells were transferred to RPMI 1640 without phenol red supplemented with 1% BSA and 50 U/ml penicillin–streptomycin (assay medium). To assess FPR2 activation, we measured FPR2-specific Ca\(^{2+}\) fluxes. HL-60 FPR2 cells were washed twice with assay medium. 1.5 × 10\(^6\) cells in 1.5 ml medium were mixed with 5 µM Fluo-3-AM (F14218, Invitrogen, Waltham, Massachusetts, USA) dissolved in DMSO (472301, Sigma–Aldrich, St. Louis, Missouri, USA) and incubated in a cell culture incubator at 37°C and 5% CO\(_2\) for 30 min. After incubation, cells were washed with assay medium and resuspended to a final concentration of 2 × 10\(^6\) cells per ml. To block FPR2, we added 15 µM WRW4 peptide (2262/1, Tocris Bio-Techne, Minneapolis, Minnesota, USA) dissolved in H\(_2\)O to the cells. Five hundred µl of cell suspension was pipetted into FACS tubes. Ca\(^{2+}\) fluxes were recorded by FACS (FACSCanto II, BD Bioscience, Franklin Lakes, New Jersey, USA) using a 488 nm excitation laser and 530/30 nm filter. The baseline signal was measured for 30 s. Next, peptides were added to the cells to a 1.5 µM final concentration, cells were very briefly vortexed, and Ca\(^{2+}\) fluxes were immediately recorded for up to 4 min. FlowJo (version 10.0.7r2) kinetics platform was used for initial data analysis. A time series of median fluorescence values were exported for every sample. Baseline (I\(_0\)) was established as the average signal of the first 25 s of measurement, and data were normalized using the formula (I − I\(_0\))/I\(_0\). Unless stated otherwise, maximum signals after stimulation are reported.

2.9 Statistical analysis

Student’s t-test with the Holm–Šidák multiple-comparison correction or one-way ANOVA followed by Dunnett’s or Tukey’s multiple-comparisons test were performed as indicated. p-values lower than .05 were considered statistically significant (*p < .05; **p < .01; ***p < .001). Statistical analysis was performed with GraphPad Prism 8.

3 RESULTS

3.1 SIRL-1 is engaged by a factor secreted by staphylococci

We used 2B4 NFAT–GFP reporter cells, additionally expressing a chimeric protein consisting of the extracellular domain of human SIRL-1 and the transmembrane and intracellular domain of CD3ζ(hSIRL-1-CD3ζ) to screen for potential bacterial ligands for SIRL-1. As controls, we used non-transduced and hLAIR-1-CD3ζ-transduced 2B4 NFAT–GFP reporter cells. We stimulated all three NFAT–GFP reporter cell lines with plate-coated specific monoclonal antibodies against mouse CD3, hLAIR-1 (clone 8A8) or hSIRL-1 (clone 1A5), or collagen I. All three cell lines highly expressed GFP upon stimulation with anti-mouse CD3, which ligates the endogenous mouse CD3 protein expressed by the 2B4 NFAT–GFP cell line (Figure 1A). Stimulation with anti-LAIR-1 and anti-SIRL-1 antibodies induced
FIGURE 3 Synthetic *Staphylococcus aureus* PSMα3 and δ-toxin and human cathelicidin LL-37 selectively activate SIRL-1. (A–D) Wild-type, hLAIR-1-CD3ζ, or hSIRL-1-CD3ζ-expressing NFAT–GFP reporter cells were stimulated overnight with a concentration range of up to 60 µM of plate-coated PSMα3, N'-formylated PSMα3, N'-formylated PSMβ1, and N'-formylated δ-toxin of *S. aureus* (A) and human cathelicidin LL-37 (C), as indicated. In B and D, only stimulations with 60 µM plate-coated peptides are shown for all three reporter cell lines. (E–H) hLAIR-1-CD3ζ- or hSIRL-1-CD3ζ-expressing NFAT–GFP reporter cells were pre-incubated with anti-hLAIR-1 and two different anti-hSIRL-1 antibodies, and then stimulated overnight with plate-coated anti-mCD3 (E), collagen I (F), PSMα3 (G), or LL-37 (H) as indicated. GFP expression upon stimulation was measured by flow cytometry (A–H). (I, J) Visualization (I) and quantification (J) of NFAT translocation into the nucleus 30 min after stimulation of the hSIRL-1-CD3ζ GFP reporter cell line with PBS, phorbol 12-myristate 13-acetate and ionomycin (PMA + iono.), and plate-coated anti-CD3, anti-LAIR-1, anti-SIRL-1, PSMα3, and cathelicidin LL-37 were assessed by ImageStream. Mean and SD of three independent experiments are displayed. (B, D–H) Student’s t-test with the Holm–Šidák multiple-comparison correction (no correction in D). (B, D) Significance is indicated for the comparison of hLAIR-1-CD3ζ to hSIRL-1-CD3ζ. (E–H) Significance is indicated for the comparison of anti-hLAIR-1 (8A8) to anti-hSIRL-1 (1A5) pre-incubation of reporter cells. (J) One-way ANOVA followed by Dunnett’s multiple-comparisons test. Significance is indicated for the comparison of PBS to all other conditions.

*p < .05; **p < .01; ***p < .001; ns = not significant
high GFP expression only in the respective cell lines, demonstrating specificity (Figure 1A). Additionally, the hLAIR-1-CD3ζ reporter cell line was stimulated with plate-coated collagen I, one of many types of collagens that are natural ligands of LAIR-1, resulting in up to 70% GFP-positive cells (Figure 1A). Next, we stimulated the reporter cell lines with plate-coated overnight supernatants of *S. aureus* strains LAC and MW2. Supernatants from both strains induced GFP expression in hSIRL-1-CD3ζ reporter cells, resulting in around 60% GFP-positive cells (Figure 1A,B). We observed no response in hLAIR-1-CD3ζ reporter cells, indicating specificity for SIRL-1 (Figure 1A,B). The bacterial culture broth, tryptic soy broth, induced only minimal GFP expression in the hSIRL-1-CD3ζ line (Figure 1A,B). To determine whether the potential SIRL-1 ligand was conserved among other staphylococcal species, we stimulated the reporter cell lines with overnight supernatants of nine additional staphylococcal species (Figure 1C). All supernatants induced GFP expression in hSIRL-1-CD3ζ reporter cells, whereas none induced GFP expression in hLAIR-1-CD3ζ or wt reporter cells. This shows that a potential bacterial SIRL-1 ligand is conserved among staphylococci.
3.2 | Staphylococcal agr operon controls expression of the SIRL-1-activating factor

*S. aureus* is the most intensely studied member of the genus *Staphylococcus*, with a wealth of research tools available to study its biology. To identify the staphylococcal SIRL-1 ligand, we screened the supernatants of all 1920 arrayed *S. aureus* mutants from the NTML for their ability to activate SIRL-1 as measured by induction of GFP expression in the hSIRL-1-CD3ζ reporter cells (Figure 2A). Nineteen mutants induced percentages of GFP-positive hSIRL-1-CD3ζ reporter cells equal to or lower than the background levels (6.4% GFP-positive reporter cells) induced by tryptic soy broth used to cultivate bacteria (Figure 2A, dashed line). Fifteen of these mutants are mutated in proteins normally not secreted from *S. aureus*, and one is a mutant of a putative membrane protein. These sixteen mutants are listed in the Appendix Table A1, and we excluded them from further analysis. We next focused on the remaining three Tn-insertion mutants that induced percentages of GFP-positive cells lower than the background. Two of these Tn-insertion mutants were mutated in genes *agrB* and *agrC* (4.8% and 5.7% GFP-positive reporter cells, respectively; Figure 2A, red dots below background dashed line), which are part of the *agr* operon. The *agr* operon comprises four genes *agrA–agrD*. Additionally, a Tn-insertion mutant in the third gene of the *agr* operon, *agrA*, induced 7.2% GFP-positive reporter cells, which is slightly above background (Figure 2A, red dot above background dashed line), whereas the fourth gene *agrD* is not present in the NTML. The third Tn-insertion mutant of interest was mutated in *sarA* (5.3% GFP-positive reporter cells; Figure 2A, green dot).

The *agr* operon encodes the *S. aureus* quorum sensing (QS) system, which consists of four cooperatively acting proteins AgrA–AgrD and controls the expression of accessory genes such as toxins, adhesins, and other proteins essential for biology and virulence of staphylococci. The gene *sarA* encodes the staphylococcal accessory regulator A (SarA), which controls the transcription of the *agr* operon. AgrD is a small peptide secreted through the cell wall-residing AgrB into the extracellular space, where it accumulates with the increasing density of bacterial population. High concentrations of AgrD activate the cell wall-residing receptor histidine kinase AgrC. Activated AgrC, in turn, phosphorylates the cytoplasmic response regulator AgrA, which in conjunction with SarA initiates transcription from *agr* promoters. Our data show that the *agr* system either regulates the secretion of a potential SIRL-1 ligand in *S. aureus* or that its components themselves induce GFP expression in the SIRL-1 reporter cell line. AgrD is the only one of the four Agr proteins that is not inactivated in the NTML but also the only secreted Agr protein, making it a likely candidate for SIRL-1 activation. In line with this, inactivation of AgrB, which is required for AgrD secretion, results in significant decrease in SIRL-1 activation. Nevertheless, inactivation of AgrA/C also results in abrogation of SIRL-1 activation, and secretion of AgrD is not dependent on AgrA/C. It is, therefore, unlikely that AgrD itself is the SIRL-1-activating molecule. Instead, the *agr*-encoded QS system components of *S. aureus* probably regulate the secretion of a SIRL-1 ligand. To test this hypothesis, we stimulated the hSIRL-1-CD3ζ reporter cells with supernatants of NTML mutants in regulatory proteins that are under control of the *agr* system. These included mutants in the pentose phosphate pathway-responsive regulator *rplR*, repressor of toxins *rot*,...
endoribonuclease III mc, and in two main staphylococcal protein secretion pathways—twin-arginine translocation system tat/tatC and the secretion system secA/secY—which are responsible for the transmembrane transport of most Staphylococcus aureus secreted proteins. Supernatants from all these mutants induced GFP expression in hSIRL-1-CD3ζ reporter cells, in contrast to the supernatants of sarA, agrA, agrB, and agrC NTML Tn-insertion mutants, which only induced minimal GFP expression (Figure 2B). Our data show that the SIRL-1 ligand secreted by S. aureus is directly regulated by the agr system and not through an interconnected regulatory system downstream of the agr system. Furthermore, it is not secreted via the major staphylococcal secretion systems Tat or Sec.

3.3 Staphylococcal α-type phenol-soluble modulins (PSMs) activate SIRL-1

The staphylococcal QS system also controls the expression of PSMs, a family of peptides with distinct structural and functional characteristics, almost universally expressed by staphylococci. PSMs are amphipathic α-helical peptides, that is, polar amino acids partition on one side of the helix and hydrophobic ones on the other.33 Many PSMs are cytotoxic to human cells.33,46 PSMs are typically formylated on the N’-terminal methionine and can activate the chemotactic FPR2 on immune cells.32 In S. aureus, the shorter α-type PSMs (20 to 26 amino acids) comprise PSMα1-4 and δ-toxin (hld), while the longer β-type PSMs comprise PSMβ1-2 (44 amino acids). The expression of psm genes is strictly controlled by the direct binding of AgrA to the psm promoter region.46 We tested overnight supernatants of the following independently generated deletion mutants: a quadruple agrABCD mutant lacking all four QS genes (Δagr),33 a triple deletion mutant in PSMα1-4, PSMβ1-2, and δ-toxin hld (ΔPSM),34 and single deletion mutants in PSMα1-4 (ΔPSMα), PSMβ1-2 (ΔPSMβ), or δ-toxin (Δhld). To exclude strain-specific effects, we used mutants in two different genetic backgrounds, S. aureus strains LAC and MW2. Δagr, ΔPSM, and ΔPSMα1-4 in both genetic backgrounds showed significantly decreased SIRL-1 activation in the reporter cell line, while ΔPSMβ1-2 and Δhld have no or very little (hld) effect on GFP expression, showing that PSMα1-4 are possibly the SIRL-1 ligands (Figure 2C,E).

To confirm that genes encoding PSMα1-4 confer SIRL-1-activating properties to S. aureus supernatants and exclude possible unwanted in cis effects of gene deletions, we performed a gene complementation study. Tetracycline resistance-bearing pTXΔ16 plasmids encoding PSMα1-4 (p-PSMα), PSMβ1-2 (p-PSMβ), or δ-toxin (p-hld) under control of constitutively active staphylococcal xylose promoter were introduced into the ΔPSM strain. Empty pTXΔ16 plasmid backbone was introduced into wt and ΔPSM strains as a control. We performed the plasmid complementation in Staphylococcus LAC (Figure 2D) and S. aureus MW2 (Figure 2F) genetic backgrounds. Reintroduction of genes encoding PSMα1-4, but not PSMβ1-2, into ΔPSM mutants restored SIRL-1 reporter cell line activation to the levels induced by supernatants of wt strains. In contrast to our results with the hld deletion strains (Figure 2C,E), reintroduction of the gene encoding the δ-toxin (p-hld) restored the SIRL-1-activating phenotype exhibited by the wt strain (Figure 2D,F). Notably, in S. aureus LAC, p-hld complementation resulted in lower numbers of GFP-positive SIRL-1 reporter cells compared to the wt strain. In S. aureus MW2, this difference was not significant, which we attribute to slight variability in data. A possible explanation for the observed restoration of SIRL-1 activation in the p-hld complemented strains while the hld deletions showed no effect on SIRL-1 activation is that in overnight supernatants of wt strains, the amounts of PSMα1-4 may be higher than the amounts of δ-toxin and may compensate for the effect of hld deletion. Furthermore, plasmid-encoded PSM genes are not controlled by their native promoter, but instead by a constitutively active xylose promoter. Additionally, the copy number of genes encoding PSMs on the plasmid is higher than on the chromosome. Both factors may result in higher supernatant concentrations of PSMs when expressed from the plasmid than when expressed from the chromosome. The empty vector backbone introduction into either wt or ΔPSM backgrounds did not have any noticeable effect on GFP expression (Figure 2D,F).

To verify that no other bacterial co-factors were required for SIRL-1 activation, we determined whether synthetic α-type PSMs activated the hSIRL-1-CD3ζ reporter cell line. Naturally produced PSMs are predominantly N’ terminal formylated. We stimulated reporter cells with plate-coated S. aureus N’-formyl-PSMα3, N’-formyl-PSMβ1, N’-formyl-δ-toxin, and non-formylated PSMα3. The hSIRL-1-CD3ζ reporter cell line was selectively activated by N’-formyl-PSMα3, non-formylated PSMα3, and N’-formyl-δ-toxin, but not N’-formyl-PSMβ1, which is in line with our previous observations using bacterial gene knockouts (Figure 2C,E). The formylation status of PSMα3 did not affect SIRL-1 activation. Notably, the observed SIRL-1-activating effect was concentration dependent (Figure 3A) and receptor specific, since wt and hLAIR-1-CD3ζ reporter cell lines did not respond to any of the synthetic peptides (Figure 3B).

3.4 Human antimicrobial peptide cathelicidin LL-37 activates SIRL-1

Cathelicidin LL-37 is a human host defense peptide that shows biochemical, structural, and functional similarities
to α-type PSMs. It is a 37 AA long amphipathic α-helical peptide constitutively expressed by epithelial cells at barrier sites, such as the skin, and acts as a first defense against invading microbes. Additionally, activated immune cells secrete it in high amounts to promote the inflammatory process. LL-37 is produced by cleavage of its precursor protein hCAP18 by kallikrein in keratinocytes and proteinase 3 in neutrophils. It interacts with the membranes of bacteria and eukaryotic cells, impairing membrane integrity through pore formation, resulting in cytolyis. Sub-cytolytic concentrations, LL-37 also regulates the immune system through binding to FPR2, promoting immune cell activation to clear pathogens. We stimulated the hSIRL-1-CD3ζ reporter cells with increasing concentrations of plate-coated LL-37 and observed that this α-helical peptide activated the hSIRL-1-CD3ζ, but not wt or hLAIR-1-CD3ζ, reporter cells in a concentration-dependent manner (Figure 3C,D). This observation identifies a new endogenous candidate ligand for SIRL-1.

### 3.5 | SIRL-1 activation by PSMs and LL-37 is blocked by specific antibodies

To further demonstrate that the observed GFP signal is SIRL-1 specific, we pre-incubated the hSIRL-1-CD3ζ reporter cells with two different anti-SIRL-1 antibodies (clones 1A5 and 3D3) or with the anti-LAIR-1 antibody (clone 8A8) before incubation on plate-coated PSMα3, LL-37, and anti-CD3 antibody as control (Figure 3E–H). Pre-incubation of hSIRL-1-CD3ζ reporter cells with anti-LAIR-1 or any of the anti-SIRL-1 antibodies did not affect the reporter cell activation by plate-coated anti-CD3 (Figure 3E). As an additional control, hLAIR-1-CD3ζ reporter cells were pre-incubated with anti-LAIR-1 and both anti-SIRL-1 antibodies and subsequently stimulated with plate-coated collagen I. While anti-LAIR-1 blocked collagen I-induced LAIR-1 activation, none of the anti-SIRL-1 antibodies did so (Figure 3F). Both anti-SIRL-1 antibodies blocked the interaction between PSMα3 or LL-37 and SIRL-1 in a concentration-dependent manner (Figure 3G,H). Thus, we have further confirmed that PMSα3- and LL-37-induced GFP expression is specific for SIRL-1 and requires the SIRL-1 ectodomain.

To further investigate whether PSMs and LL-37 directly activate SIRL-1, we sought to measure reporter cell activation in a transcription-independent manner. We visualized and quantified the translocation of NFAT from the cytoplasm to the nucleus 30 min after incubation of hSIRL-1-CD3ζ reporter cells with PBS, PMA–ionomycin, anti-CD3, anti-SIRL-1, anti-LAIR-1, PSMα3, or cathelicidin LL-37 (Figure 3I shows visualization, and Figure 3J shows quantification). We observed NFAT translocation from the cytoplasm into the nucleus after incubation with PMA–ionomycin, anti-CD3, and anti-SIRL-1, but not PBS or anti-LAIR-1, showing specificity (Figure 3I). Incubation with both PSMα3 and cathelicidin LL-37 resulted in a substantial increase in nuclear NFAT (Figure 3J). These data strongly suggest that both S. aureus PSMα3 and human cathelicidin LL-37 directly activate SIRL-1.

### 3.6 | SIRL-1 is broadly activated by staphylococcal PSMs

Virtually, all staphylococcal species express PSMs. At least 12 different PSMs and similar peptides are identified in S. aureus: PSMα1-4, PSMβ1-2, δ-toxin, and its allelic variant G10S. Furthermore, specific sub-types of methicillin-resistant S. aureus strains also possess PSM-Mec. Additionally, three N’-terminal fragments of the QS protein AgrD of S. aureus—N-AgrD F20, N-AgrD F24, and N-AgrD D20—have been identified with properties remarkably similar to other PSMs. In S. epidermidis, PSMβ1-3, PSMα, PSMγ/δ-toxin, PSMδ, and PSMε were identified. Furthermore, PSMβ1-3 and PSMα in S. haemolyticus homologs of S. epidermidis PSM in S. lugdunensis, S. pseudintermedius, and S. warneri, and the OrfX peptide in S. lugdunensis are described. We synthesized these PSMs and stimulated the reporter cell lines with them (Figure 4A–C). All shorter PSMα-type peptides of S. aureus, except for PSM-Mec and the N’-terminal fragments of AgrD, strongly activated the hSIRL-1-CD3ζ, but not wt or hLAIR-1-CD3ζ, reporter cell line (Figure 4A). The longer PSMβ-type peptides did not induce significant GFP expression in hSIRL-1-CD3ζ reporter cells (Figure 4A). Similarly, PSMε-type peptides of S. epidermidis and other staphylococci activated the hSIRL-1-CD3ζ, but not wt or hLAIR-1-CD3ζ, reporter cell line, while PSMβ-type peptides did not (Figure 4B,C). Therefore, we conclude that short, PSMα-like PSMs across the genus Staphylococcus activate SIRL-1.

### 3.7 | SIRL-1 recognizes amphipathic α-helical peptides

Among staphylococcal PSMs, sequence identity is low. The pairwise sequence identities between SIRL-1-activating S. aureus PSMα3 and other SIRL-1-activating PSMs shown in Figure 4 range from 16% for S. lugdunensis OrfX to 41% for S. aureus PSMε2, and the average pairwise sequence identity is only 24%. On the other hand, general structural properties are much more conserved among PSMs. In these peptides, the alternating arrangement of charged and hydrophobic amino acids from the N’ to the C’ terminus...
results in their partitioning to the opposite sides of the α-helix, giving rise to amphipathicity. Furthermore, an overall positive charge is seen in all SIRL-1-activating PSMs (except for *S. epidermidis* PSMα, which has a zero net charge but is still amphipathic). The same structural features are also recognized in the human cathelicidin LL-37, while its sequence identity to PSMs is low. To explore the structure–function relationship in SIRL-1-activating PSMs, we investigated how PSM-mediated SIRL-1 activation is affected by structural changes in PSMs such as change in chirality or C’–N’ sequence reversal. We stimulated the hSIRL-1-CD3ζ reporter cell line with the all-D isomer of *S. aureus* PSMα3 or with C’–N’ PSMα3 and observed that these peptides activated SIRL-1 in the GFP reporter assay equally potently as the wt PSMα3 (Figure 5A,B). This observation supports the idea that SIRL-1 recognizes a general molecular feature of staphylococcal PSMs instead of a particular amino acid sequence.

To further explore the structural characteristics of SIRL-1-activating peptides, we designed a series of PSM- and LL-37-inspired peptides with differing properties and tested these in wt, hLAIR-1-CD3ζ, and hSIRL-1-CD3ζ reporter cells (Figure 5C, Table 3). We varied the amino acid composition and their positioning in the α-helix to vary: (1) overall/net charge of the helix; (2) partitioning of the charged and hydrophobic residues along the helix; and (3) overall hydrophobicity. We chose amino acids with the highest propensities to form α-helices:38 lysine to incorporate a positive charge, glutamic acid to incorporate a negative charge, glutamine as a polar uncharged amino acid, and leucine as a hydrophobic amino acid, and performed secondary structure prediction for all designed peptides. Most peptides were strongly predicted to have α-helical secondary structure, except for peptides no. 2, 8, and 10–12, for which the α-helical secondary structure prediction was less reliable. The secondary structure of peptide no. 6 could not be confidently predicted. To illustrate the peptides’ amphipathicity, we plotted them as helical wheels (Figure 5C, peptide no. 1 is an example of an amphipathic peptide). Using this panel of rationally designed artificial peptides, we observed that all peptides with a predicted α-helical secondary structure and amphipathic arrangement of hydrophobic residues activated SIRL-1 (Figure 5C). Notably, scrambling the positions of amino acids to disturb their separation to the polar and hydrophobic faces, and consequently, entirely disrupt the amphipathic character, while keeping the amino acid content unchanged, abrogated SIRL-1 activation (Figure 5C, peptide pairs 1-2, 3-4, and 7-8), except in the peptide pairs 5-6 (Figure 5C). The specific composition of the helix’s polar face had little effect on SIRL-1-activating properties of the peptides (Figure 5C, peptides 13-28).

### 3.8 Some artificial SIRL-1-activating peptides are non-toxic and do not activate FPR2

Most PSMs are highly cytotoxic and act pro-inflammatory by activating the chemotactic receptor FPR2 on immune cells.52 We tested if the cytotoxic and FPR2-activating properties of our panel of designed peptides could be segregated from the SIRL-1-engaging property. We first assessed the cytotoxicity of all designed peptides by measuring LDH release from hSIRL-1-CD3ζ reporter cells upon treatment with 10 μM peptides. All derivatives of *S. aureus* PSMα3 (PSMα3, N’-formyl-PSMα3, all-D-PSMα, and C’–N’ PSMα3) exhibited cytotoxicity (Figure 5D). In contrast, designed peptides 1-4, 7-12, and 18-22 were not cytotoxic at the same concentration (Figure 5D). We next screened a selection of non-toxic peptides for FPR2 activation by measuring Ca2+ mobilization in the HL-60 cell line overexpressing FPR2. *S. aureus* PSMα3 and its naturally occurring N’-formylated variant potently activated FPR2 (a representative transient Ca2+ signal induced by PSMα3 is shown in Figure 5E), and Ca2+ signaling was entirely inhibited when cells were pre-incubated with the FPR2 inhibitory peptide WRW4 (Figure 5E,F). The C’–N’ PSMα3 and all-D-PSMα3 did not activate FPR2, in line with previously published data.52 None of the tested artificial SIRL-1-activating peptides activated FPR2 (Figure 5E,F). Therefore, cytotoxicity, FPR2 activation, and SIRL-1 engagement have different structural requirements. We here identified peptides 1, 3, and 18-22 as non-cytotoxic and non-FPR2-activating SIRL-1-specific agonists.

### 4 DISCUSSION

Here, we demonstrate that secreted staphylococcal α-helical peptides, PSMs,46,49 activate the human inhibitory receptor SIRL-1. Our data show that in *S. aureus*, PSMs are the primary SIRL-1-activating compound, as PSM-deficient mutant strains have considerably decreased SIRL-1-activating properties. Nevertheless, PSM-deficient mutants still weakly engage SIRL-1, hinting at possible additional SIRL-1-activating factors secreted by staphylococci. For instance, these could be additional not yet characterized PSMs or similar molecules. We show that synthetic PSMs from other staphylococcal species also activate SIRL-1, demonstrating that SIRL-1 broadly recognizes staphylococcal PSMs. We further demonstrate that SIRL-1 is activated by the human peptide cathelicidin LL-37, which has structural and functional similarities to staphylococcal PSMs.19 Taken together, we have identified a new group of bacterial and endogenous SIRL-1 ligands—the staphylococcal PSMs and the human cathelicidin LL-37.
PSMs are vital determinants of staphylococcal virulence: they are cytotoxic to different human cell types and engage the chemotactic receptor FPR2 on human neutrophils. They can be secreted in high amounts; it has been shown that as much as 60% of total secreted proteins in wt S. aureus USA300 are PSMs. However, PSMs are not only virulence factors but also perform multiple other functions. They promote the spreading of bacterial cells on the epithelial surface and facilitate the formation and structuring of biofilms. PSMs also act as bacteriocins, cytotoxic bacterial products active against other bacterial species, helping to maintain staphylococci in their habitat and protecting them and their host from other invading bacterial species. Furthermore, PSMs have immunomodulatory and tolerance-inducing properties. For example, they modulate human dendritic cells to direct the development of regulatory T cells, leading to tolerogenic immune responses. All these features identify PSMs not only as virulence factors but also as facilitators of a mutually beneficial relationship between staphylococci and their host.

The human antimicrobial peptide cathelicidin LL-37 structurally and functionally resembles the staphylococcal PSMs. It is an amphipathic α-helical peptide with cytotoxic and, through binding to FPR2, immunostimulatory properties. However, it also possesses a plethora of immunomodulatory functions; it decreases the production of pro-inflammatory and stimulates the production of anti-inflammatory cytokines in numerous cell types. For example, LL-37 decreases pro-inflammatory cytokine production in epithelial cells pre-exposed to the bacterial TLR5 agonist flagellin, decreases TNF and nitric oxide production in macrophage cell lines stimulated with LPS, LTA, or lipoarabinomannan PAMPS, and dampens the expression of IL-6, IL-8, and CXCL10 induced by LPS in human gingival fibroblasts. Future studies are needed to investigate the possibility that some of these modulatory functions are mediated by SIRL-1.

Recognition of PSMs and LL-37 by SIRL-1 does not require specific amino acid residues, which is evident from PSMs and LL-37 sharing little sequence identity. Instead, SIRL-1 may be activated by the general molecular features of these molecules. Based on the naturally occurring staphylococcal PSMs and the structurally and functionally similar human cathelicidin LL-37 that activate SIRL-1, we conclude that α-helical peptides with an amphipathic arrangement of hydrophobicity engage SIRL-1. Furthermore, structural rearrangements of PSMα3, such as in the all-D-PSMα3 isomer and the C'-N' reversed sequence PSMα3, in which α-helical secondary structure and amphipathic arrangement of hydrophobic amino acid residues are preserved, still activate SIRL-1. Similar to our observation that both L- and D-PSMα3 potently activate SIRL-1, both L-LL-37 and D-LL-37 equally induce IL-8 production in human keratinocytes, which could be blocked by surface receptor-specific inhibitors. It has been suggested that the hydrophobic environment of the cell membrane might allow for specific peptide–peptide or peptide–protein interactions irrespectively of the peptide's chirality or helix sense. We could not demonstrate a direct interaction between PSMs or LL-37 and SIRL-1 in a purified system using recombinant proteins. This may indicate that a membrane component, which is absent in purified systems, is required for SIRL-1–PSM or SIRL-1–LL-37 complex formation. Our attempts to detect interaction may have additionally been hampered by the potent and irreversible tendency of these peptides to stack into amyloid-like fibrils.

Based on the structural features of staphylococcal PSMs and the human LL-37, we rationally designed a series of peptides with predicted α-helical secondary structure and varying amphipathic character, charge, and charge distribution. We observed that the amphipathic character of these peptides is required for SIRL-1 activation, regardless of the detailed variations in their structure. Although we did not experimentally determine the secondary structure of these peptides, the predicted secondary structure, together with the peptides' SIRL-1-activating properties, support our idea that α-helical peptides with an amphipathic arrangement of hydrophobicity engage SIRL-1. Notably, scrambling the amino acids' positions to disturb their separation to the polar and hydrophobic faces, and consequently entirely disrupting the amphipathic character of the designed peptides while keeping their amino acid content unchanged, abrogated SIRL-1 engagement in all but one peptide pair (Figure 5C, peptide pairs 5-6). However, SIRL-1 engagement by both these peptides is much less prominent than with other peptides. Without further characterizing these peptides, we cannot adequately explain why peptide 6 still weakly engages SIRL-1. Finally, the charge distribution and overall charge of the artificial peptides did not have a notable effect on SIRL-1 activation.

General structural features of staphylococcal PSMs are formylation of the N'-terminal methionine, α-helical secondary structure, and amphipathic arrangement of amino acid residues. Functionally, PSMs are cytotoxic and FPR2 activating, and as we show here, they also engage SIRL-1. Using the series of designed peptides, we were able to decouple the cytotoxic and pro-inflammatory properties of these peptides from their SIRL-1-engaging function. As expected, all derivatives of PSMα3 (PSMα3, N'-formyl-PSMα3, all-D-PSMα3, and C'-N' PSMα3) exhibited cytotoxicity, while peptides with a lower net charge showed decreased or no cytotoxicity. This is in line with the fact that antimicrobial or cytotoxic peptides are commonly amphipathic and positively charged. With regard to
FPR2 activation, we confirm that C’–N’ reversed and all-D-PSMα3 completely lost the FPR2-activating property, in line with previously published data.52 Thus, we have obtained a group of LL-37- and PSM-inspired SIRL-1-engaging peptides without FPR2-activating and cytotoxic properties, demonstrating that different structural features of PSMs and LL-37 mediate FPR2 activation, SIRL-1 activation, and cytotoxicity. Others previously showed that different epitopes of the LL-37 peptide mediate different functions and that segregation of the peptide’s functions is possible.75 The ability to segregate the versatile properties of LL-37 and the PSMs is interesting from a therapeutic perspective, since inhibitory receptors are attractive targets for immunotherapy.78

Microbes rapidly evolve and quickly change their molecular makeup. To achieve reliable recognition of microbes, the immune system employs PRRs, which recognize general structural patterns to ensure robust target recognition that is not perturbed by minor changes in the ligands. Many known PRRs recognize more than one structural pattern. For example, the receptors RAGE, TLR4, and TLR2 all recognize different patterns and bind diverse ligands.79,80 SIRL-1 may employ a similar strategy to recognize its ligands. We previously showed that SIRL-1 is activated by the human S100 proteins.11 Here, we identify staphylococcal α-type PSMs and human cathelicidin LL-37 as an additional class of SIRL-1 ligands. Both cathelicidin LL-37 and the S100 family of proteins are DAMPs and are released from damaged cells or activated immune cells to promote inflammatory processes. We have previously suggested that inhibitory receptors provide negative feedback on immune cell activation to prevent immunopathology.4 In this regard, the recognition of DAMPs such as LL-37 by SIRL-1 may enable prompt cessation of inflammatory processes and limit immunopathology. The interaction between SIRL-1 and its newly described exogenous ligands, staphylococcal PSMs, may serve a similar purpose. It may be in place to favor the commensal lifestyle of PSM-producing staphylococci over their potential to trigger host-damaging immune responses.

A genetic polymorphism causing reduced SIRL-1 expression levels on monocytes is associated with atopic dermatitis, a skin disease characterized by extensive inflammation and almost universal presence of S. aureus in atopic dermatitis skin lesions.7,22 On the other hand, atopic dermatitis is correlated with significantly lower or even insufficient LL-37 expression, especially after skin injury,81–83 while in other inflammatory skin diseases, such as rosacea and psoriasis,84,85 LL-37 expression is commonly increased. Together, this may suggest that the malfunction or absence of the PSM/LL-37–SIRL-1 regulatory axis, which would deliver inhibitory signals to immune cells, contributes to the development of inflammatory diseases like atopic dermatitis.

To conclude, we have demonstrated that SIRL-1 is activated by α-helical peptides with an amphipathic arrangement of hydrophobicity, namely the human cathelicidin LL-37 and the staphylococcal PSMs. We designed SIRL-1-specific activating peptides without cytotoxic and chemotactic properties. This will allow us to unravel the biology of SIRL-1 further and will facilitate the development of SIRL-1 agonists for possible therapeutic intervention in autoimmune and inflammatory diseases.

ACKNOWLEDGMENTS
We want to thank Bas Surewaard for providing the following plasmids: pTXΔ16, pTXΔ16–PSMα, pTXΔ16–PSMβ, and pTXΔ16–hld. This work was supported by a Vici grant from the Netherlands Organization for Scientific Research awarded to LM (NWO, grant no. 91815608).

DISCLOSURES
The authors state explicitly that there are no conflicts of interest to declare in connection with this article.

AUTHOR CONTRIBUTIONS
MR, NMv.S., and LM designed the study. MR, HJv.R., M.v.d.L., and GHAW performed the experiments and analyzed the data. CTO synthesized the peptides. MR wrote the manuscript. All authors except HO contributed to the reviewing and editing of the final manuscript. ML, HO, NMv.S., and LM supervised the study. LM acquired funding for the study.

ORCID
Matevž Rumpret https://orcid.org/0000-0002-8631-8049
Helen J. von Richthofen https://orcid.org/0000-0002-2062-5986
Maarten van der Linden https://orcid.org/0000-0001-8597-4151
Cami Talavera Ormeño https://orcid.org/0000-0001-5502-2985
Jos A. G. van Strijp https://orcid.org/0000-0001-6253-0830
Meytal Landau https://orcid.org/0000-0002-1743-3430
Nina M. van Sorge https://orcid.org/0000-0002-2695-5863
Linde Meyaard https://orcid.org/0000-0003-0707-4793

REFERENCES
1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801.
2. Yang D, Yang Z, Oppenheim JJ. Alarmins and immunity. Immuno Rev. 2017;280:41–56.
3. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1–5.
4. Rumpret M, Drylewicz J, Ackermans LJE, Borghans JAM, Medzhitov R, Meyaard L. Functional categories of immune inhibitory receptors. Nat Rev Immunol. 2020;20:771–780.
5. Steevels TA, Lebbink RJ, Westerlaken GH, Coffer PJ, Meygaard L. Signal inhibitory receptor on leukocytes-1 is a novel functional inhibitory immune receptor expressed on human phagocytes. *J Immunol*. 2010;184:4741-4748.

6. von Richthofen HJ, Gollnast D, van Capel TMM, et al. Signal inhibitory receptor on leukocytes-1 is highly expressed on lung monocytes, but absent on mononuclear phagocytes in skin and colon. *Cell Immunol*. 2020;357:104199.

7. Kumar D, Puan KJ, Andiappan AK, et al. A functional SNP associated with atopic dermatitis controls cell type-specific methylation of the VSTM1 gene locus. *Genome Med*. 2017;9:18.

8. Steevels TA, van Avondt K, Westerlaken GH, et al. Signal inhibitory receptor on leukocytes-1 (SIRL-1) negatively regulates the oxidative burst in human phagocytes. *Eur J Immunol*. 2013;43:1297-1308.

9. Van Avondt K, Fritsch-Stork R, Derksen RH, Meyuard L. Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus. *PLoS One*. 2013;8:e78459.

10. Van Avondt K, van der Linden M, Naccache PH, Egan DA, Meyuard L. Signal inhibitory receptor on leukocytes-1 limits the formation of neutrophil extracellular traps, but preserves intracellular bacterial killing. *J Immunol*. 2016;196:3686-3694.

11. Rumpret M, von Richthofen HJ, van der Linden M, et al. Recognition of S100 proteins by Signal Inhibitory Receptor on Leukocytes-1 negatively regulates human neutrophils. *Eur J Immunol*. 2021;51:2210-2217.

12. Besteman SB, Callaghan A, Hennus MP, Westerlaken GHA, Meyuard L, Bont LL. Signal inhibitory receptor on leukocytes (SIRL)-1 and leukocyte-associated immunoglobulin-like receptor (LAIR)-1 regulate neutrophil function in infants. *Clin Immunol*. 2020;211:108324.

13. Christensen GJ, Bruggemann H. Bacterial skin commensals and their role as host guardians. *Benef Microbes*. 2014;5:201-215.

14. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? *Br J Dermatol*. 2008;158:442-455.

15. Glaser R, Harder J, Lange H, Bartels J, Christophers E, Schroder JM. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. *Nat Immunol*. 2005;6:57-64.

16. Schroder JM, Harder J. Human beta-defensin-2. *Int J Biochem Cell Biol*. 1999;31:645-651.

17. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. *Trends Immunol*. 2009;30:131-141.

18. Schittek B. The multiple facets of dermcidin in cell survival and host defense. *J Innate Immun*. 2012;4:349-360.

19. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol*. 2012;280:22-35.

20. Krismer B, Weidenmaier C, Zipperer A, Peschel A. The complementary lifestyle of *Staphylococcus aureus* and its interactions with the nasal microbiota. *Nat Rev Microbiol*. 2017;15:675-687.

21. Williams MR, Nakatsuji T, Gallo RL. *Staphylococcus aureus*: master manipulator of the skin. *Cell Host Microbe*. 2017;22:579-581.

22. Geoghegan JA, Irvine AD, Foster TJ. *Staphylococcus aureus* and atopic dermatitis: a complex and evolving relationship. *Trends Microbiol*. 2018;26:484-497.

23. Lowy FD. *Staphylococcus aureus* infections. *N Engl J Med*. 1998;339:520-532.

24. Edwards AM, Massey RC. How does *Staphylococcus aureus* escape the bloodstream? *Trends Microbiol*. 2011;19:184-190.

25. Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. *Clin Microbiol Rev*. 2014;27:870-926.

26. Brown MM, Horswill AR. *Staphylococcus epidermidis*: skin friend or foe? *PLoS Pathog*. 2020;16:e1009026.

27. Byrd AL, Belkaid Y, Seger JA. The human skin microbiome. *Nat Rev Microbiol*. 2018;16:143-155.

28. O’Riordan K, Lee JC. *Staphylococcus aureus* capsular polysaccharides. *Clin Microbiol Rev*. 2004;17:218-234.

29. Foster TJ. Immune evasion by staphylococci. *Nat Rev Microbiol*. 2005;3:948-958.

30. de Jong NW, van Kessel KPM, van Sijp JAG. Immune evasion by *Staphylococcus aureus*. *Microbiol Spectr*. 2019;7.

31. Otto M, O'Mahoney DS, Guina T, Klebanoff SJ. Activity of *Staphylococcus epidermidis* phenol-soluble modulus peptides expressed in *Staphylococcus carnosus*. *J Infect Dis*. 2004;190:748-755.

32. Van Avondt K, van Sorge NM, Meyuard L. Bacterial immune evasion through manipulation of host immune signaling. *PLoS Pathog*. 2015;11:e1004644.

33. Wang R, Braughton KR, Kretschmer D, et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. *Nat Med*. 2007;13:1510-1514.

34. Joo HS, Cheung GY, Otto M. Antimicrobial activity of community-associated methicillin-resistant *Staphylococcus aureus* is caused by phenol-soluble modulin derivatives. *J Biol Chem*. 2011;286:8933-8940.

35. Periasamy S, Joo HS, Duong AC, et al. How *Staphylococcus aureus* biofilms develop their characteristic structure. *Proc Natl Acad U S A*. 2012;109:1281-1286.

36. Dastgheyb SS, Villaruz AE, Le KY, et al. Role of phenol-soluble modulins in formation of *Staphylococcus aureus* biofilms in synovial fluid. *Infect Immun*. 2015;83:2966-2975.

37. Nakamura Y, Oscherwitz J, Cease KB, et al. *Staphylococcus* delta-toxin induces allergic skin disease by activating mast cells. *Nature*. 2013;503:397-401.

38. Nick Pace C, Martin SJ. A helix propensity scale based on experimental studies of peptides and proteins. *Biophys J*. 1998;75:422-427.

39. Sievers F, Wilm A, Dineen D, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol*. 2011;7:539.

40. Drozdetskiy A, Cole C, Procter J, Barton GJ. JPreD4: a protein secondary structure prediction server. *Nucleic Acids Res*. 2015;43:W389-W394.

41. Gautier R, Douguet D, Antony B, Drin G. HELIQUEST: a web server to screen sequences with specific alpha-helical properties. *Bioinformatics*. 2008;24:2101-2102.

42. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Of high-quality protein multiple sequence alignments using Clustal Omega. *Acad Sci U S A*. 2011;108:1281-1286.

43. Schittek B. Multiple facets of dermcidin in cell survival and host defense. *J Innate Immun*. 2012;4:349-360.

44. Vanden dM, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol*. 2012;280:22-35.

45. Krismer B, Weidenmaier C, Zipperer A, Peschel A. The complementary lifestyle of *Staphylococcus aureus* and its interactions with the nasal microbiota. *Nat Rev Microbiol*. 2017;15:675-687.

46. Williams MR, Nakatsuji T, Gallo RL. *Staphylococcus aureus*: master manipulator of the skin. *Cell Host Microbe*. 2017;22:579-581.

47. Geoghegan JA, Irvine AD, Foster TJ. *Staphylococcus aureus* and atopic dermatitis: a complex and evolving relationship. *Trends Microbiol*. 2018;26:484-497.

48. Lowy FD. *Staphylococcus aureus* infections. *N Engl J Med*. 1998;339:520-532.
45. Schwartz K, Sekedat MD, Syed AK, et al. The AgrD N-terminal leader peptide of Staphylococcus aureus has cytolytic and amyloidogenic properties. *Infect Immun*. 2014;82:3837-3844.

46. Otto M. Phenol-soluble modulins. *Int J Med Microbiol*. 2014;304:164-169.

47. Wang R, Khan BA, Cheung GY, et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. *J Clin Invest*. 2011;121:238-248.

48. Da F, Joo HS, Cheung GYC, et al. Phenol-soluble modulin toxins of Staphylococcus haemolyticus. *Front Cell Infect Microbiol*. 2017;7:206.

49. Cheung GY, Joo HS, Chatterjee SS, Otto M. Phenol-soluble modulins—critical determinants of staphylococcal virulence. *FEMS Microbiol Rev*. 2014;38:698-719.

50. Rautenberg M, Joo HS, Otto M, Peschel A. Neutrophil responses to staphylococcal pathogens and commensals via the formyl peptide receptor 2 relates to phenol-soluble modulin release and virulence. *FASEB J*. 2011;25:1254-1263.

51. Lebbink RJ, de Ruiter T, Adelmeyer J, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1. *J Exp Med*. 2006;203:1419-1425.

52. Kretschmer D, Gleske AK, Rautenberg M, et al. Human formyl peptide receptor 2 senses highly pathogenic *Staphylococcus aureus*. *Cell Host Microbe*. 2010;7:463-473.

53. Novick RP, Geisinger E. Quorum sensing in staphylococci. *Annu Rev Genet*. 2008;42:541-564.

54. Lyon GJ, Mayville P, Muir TW, Novick RP. Rational design of a global inhibitor of the virulence response in *Staphylococcus aureus*, based in part on localization of the site of inhibition to the receptor-histidine kinase, AgrC. *Proc Natl Acad Sci U S A*. 2000;97:13330-13335.

55. Cheung AL, Projan SJ. Cloning and sequencing of sarA of *Staphylococcus aureus*, a gene required for the expression of agr. *J Bacteriol*. 1994;176:4168-4172.

56. Tayeb-Fligelman E, Tabachnikov O, Moshe A, et al. The cytotoxic *Staphylococcus aureus* PSMalpha3 reveals a cross-alpha amyloid-like fibril. *Science*. 2017;355:831-833.

57. Engelberg R, Landau M. The human LL-37(17–29) antimicrobial peptide reveals a functional supramolecular structure. *Nat Commun*. 2020;11:3894.

58. Malm J, Sorensen O, Persson T, et al. The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. *Infect Immun*. 2000;68:4297-4302.

59. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. *J Biol Chem*. 1997;272:15258-15263.

60. Hase K, Eckmann L, Leonard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. *Infect Immun*. 2002;70:953-963.

61. Bals R, Wang X, Zasloff M, Wilson JM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. *Proc Natl Acad Sci U S A*. 1998;95:9541-9546.

62. Xhindoli D, Pacor S, Benincasa M, Scoccoli M, Gennaro R, Tossi A. The human cathelicidin LL-37–A pore-forming antibacterial peptide and host-cell modulator. *Biochim Biophys Acta*. 2016;1858:546-566.

63. Morizane S, Yamasaki K, Kabibling FD, Gallo RL. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. *J Invest Dermatol*. 2010;130:1297-1306.

64. Sorensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood*. 2001;97:3951-3959.

65. Oren Z, Lerman JC, Gumdunsson GH, Agerberth B, Shay I. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. *Biochem J*. 1999;341(Pt 3):501-513.

66. Thennarasu S, Tan A, Penumatchu R, Shelburne CE, Heyl DL, Ramamoorathy A. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. *Biophys J*. 2010;98:248-257.

67. Coffelt SB, Tomchuck SL, Zweidaryk KJ, Danka ES, Scardurro AB. Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. *Mol Cancer Res*. 2009;7:907-915.

68. Tsompanidou E, Denham SL, Becher D, et al. Distinct roles of phenol-soluble modulins in spreading of *Staphylococcus aureus* on wet surfaces. *Appl Environ Microbiol*. 2013;79:886-895.

69. Schwartz K, Syed AK, Stephenson RE, Rickard AH, Boles BR. Functional amyloid composed of phenol soluble modulins stabilize *Staphylococcus aureus* biofilms. *PLoS Pathog*. 2012;8:e1002744.

70. Armbruster NS, Richardson JR, Schreiner J, Klenk J, Gunter M, Autenrieth SE. *Staphylococcus aureus* PSM peptides induce tolerogenic dendritic cells upon treatment with ligands of extracellular and intracellular TLRs. *Int J Med Microbiol*. 2016;306:666-674.

71. Richardson JR, Armbruster NS, Gunter M, Henes J, Autenrieth SE. *Staphylococcus aureus* PSM peptides modulate human monocyte-derived dendritic cells to prime regulatory T cells. *Front Immunol*. 2018;9:2603.

72. Pistolic J, Cosseau C, Li Y, et al. Host defence peptide LL-37 induces IL-6 expression in human bronchial epithelial cells by activation of the NF-kappaB signaling pathway. *J Innate Immun*. 2009;1:254-267.

73. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J Immunol*. 2002;169:3883-3891.

74. Into T, Inomata M, Shibata K, Murakami Y. Effect of the antimicrobial peptide LL-37 on Toll-like receptors 2-, 3- and 4-4 triggered expression of IL-6, IL-8 and CXCL10 in human gingival fibroblasts. *Cell Immunol*. 2010;264:104-109.

75. Braff MH, Hawkins MA, Di Nardo A, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. *J Immunol*. 2005;174:4271-4278.

76. Tomasinsig L, Pizzirani C, Skerlavaj B, et al. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. *J Biol Chem*. 2008;283:30471-30481.

77. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol*. 2005;3:238-250.
APPENDIX

TABLE A1  NTML screening hits that were excluded from further analysis

| NE number | % GFP-positive SIRL-1-CD3ζ cells | Gene | Gene product |
|-----------|----------------------------------|------|--------------|
| NE169     | 4.1                              | cap5P| Capsular polysaccharide biosynthesis protein Cap5P |
| NE352     | 5.6                              | rsgA | Ribosome small subunit-dependent GTPase A |
| NE592     | 2.8                              | atpA | ATP synthase F1, α subunit |
| NE883     | 5.4                              | xerC | Tyrosine recombinase XerC |
| NE974     | 6.4                              | mutS | DNA mismatch repair protein MutS |
| NE1048    | 4.7                              | pyrP | Uric permease |
| NE1205    | 6.4                              | nrdG | Anaerobic ribonucleotide reductase, small subunit |
| NE1262    | 4.1                              | —    | Putative membrane protein (SAUSA300_1984) |
| NE1509    | 3.0                              | mldB | ABC transporter, ATP-binding protein |
| NE1531    | 4.9                              | pdxT | Glutamine amidotransferase subunit PdxT |
| NE1656    | 4.4                              | ribD | Riboflavin biosynthesis protein |
| NE1713    | 4.9                              | alr  | Alanine racemase |
| NE1829    | 2.7                              | acoB | 2-oxoisovalerate dehydrogenase, E1 component, beta subunit |
| NE1895    | 6.4                              | argR | Arginine repressor |
| NE1896    | 2.3                              | lpdA | Dihydrolipoamide dehydrogenase |
| NE1908    | 3.4                              | ccmA | ABC transporter, ATP-binding protein |